Efficacy of Individualized Homoeopathic Intervention to Evaluate the Response in the selective inflammatory biomarkers (CBC, ESR, hS-CRP, IL-6) in Psoriasis vulgaris- Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial

Psoriasis is a chronic, non-communicable, painful, disfiguring, and disabling disease for which there is no cure and with a tremendous negative impact on a patient’s quality of life (QoL). It can occur at any age and is most common in 50–69. The prevalence of this disease reported in countries ranges between 0.09% and 11.4%, making psoriasis a severe global problem. The inflammatory nature of this disease was demonstrated by a systemic and dermal secretion of cytokines such as interleukins (IL.): IL-2, 6, 8, 12,17,18, 22, 23, 24, interferon-γ, (INF- γ) and Tumour Necrosis Factor- α (TNF- α). In addition, the IL-6 secretion induced by TNF- α leads to hepatic stimulation of the production of acute-phase reactants such as c-reactive protein (CRP) and fibrinogen. CRP is an acute-phase protein that indirectly illustrates the pro-inflammatory activity of cytokines, so it is considered an inflammatory marker and is higher in psoriasis patients than in control groups (non-psoriatic patients), along with ESR Levels. However, there are gaps concerning psoriasis and changes in the underlying inflammatory markers through individualized homoeopathic intervention. Hence, this study aims to change the inflammatory markers (via CBC, ESR, hs-CRP, IL-6) in response to Individualized homoeopathic intervention in psoriasis vulgaris and the relation of PASI score with the biomarkers.